CLINICAL RESEARCH SERVICES AGREEMENT

Pennsylvania, US

Agreement date: [date]

Sponsor: [full legal name and entity type], of [address] (Sponsor).

Provider: [full legal name and entity type], of [address] (Provider).

Study: [protocol title and number, version, investigational product or device, and phase] (Study).

1. Services and regulatory roles

Provider will perform the operational clinical-research services, deliverables, countries, sites, systems, and timelines in Schedule 1 (Services). Sponsor retains the sponsor duties imposed by applicable law except each duty expressly transferred to Provider in Schedule 2 with enough detail to identify the task and authority. A transfer does not relieve Sponsor of nondelegable oversight.

Provider is not a clinical investigator, institutional review board (IRB), health-care provider to subjects, legal representative, or manufacturer under this agreement unless Schedule 2 expressly appoints it to a lawful role. A change to scope, protocol, price, timing, or regulatory role requires a signed change order.

2. Sponsor responsibilities

Sponsor will provide the final protocol, investigator brochure or device information, safety information, investigational materials, regulatory strategy, approved consent materials, insurance or injury arrangements, accurate instructions, and timely decisions allocated to it. Sponsor will select qualified investigators and ensure required regulatory authorizations unless Schedule 2 transfers a specified task.

Sponsor will not direct Provider to begin a regulated activity before required IRB approval, informed-consent materials, site authorization, contracts, training, and product controls are in place. Sponsor remains responsible for the scientific design and for deciding whether and how to modify or stop the Study.

3. Provider performance

Provider will use qualified, trained personnel; follow the current protocol, written procedures, applicable good clinical practice, and law; maintain role-based system access; and document performance contemporaneously. Provider will promptly disclose a material deviation, conflict, inspection, disqualification concern, or inability to perform.

Provider may use a subcontractor listed in Schedule 1 or approved in writing. Provider remains responsible for subcontracted Services and will impose equivalent confidentiality, privacy, records, inspection, and quality duties.

4. Human-subject protection and safety

No subject may be enrolled or subjected to a research procedure until the applicable IRB has approved the protocol and consent process and legally effective informed consent has been obtained and documented, except when law and IRB-approved emergency procedures permit otherwise. Clinical decisions remain with qualified investigators. Neither party may pressure enrollment, conceal risk information, or pay compensation that improperly compromises subject protection.

Provider will route adverse-event, unanticipated-problem, protocol-deviation, complaint, and safety information according to the timelines and responsibility matrix in Schedule 2. An immediate threat to a subject may be escalated directly to Sponsor, the investigator, IRB, or regulator as law and safety require.

5. Data, privacy, and security

Schedule 1 identifies the data collected, systems used, permitted purposes, controller or covered-entity roles, and any required privacy or business-associate terms. Provider will collect only authorized data, follow the protocol and approved consent, use reasonable administrative, technical, and physical safeguards, and promptly notify Sponsor of unauthorized access, loss, or integrity concern.

Sponsor owns Study data and databases identified in Schedule 1, subject to subjects' rights, source-record ownership, investigator duties, and law. Provider retains its pre-existing tools and grants Sponsor a perpetual, royalty-free license to use them only as embedded in paid deliverables. No party may publish identifiable subject information.

6. Records, monitoring, and inspections

Provider will maintain complete, accurate, attributable, contemporaneous, original, and legible records for the period in Schedule 2 and any longer period applicable law or a regulator requires. Provider will not destroy Study records before Sponsor authorizes lawful disposition.

Provider will give Sponsor, monitors, auditors, IRBs, and regulators reasonable access to relevant records, systems, facilities, and personnel as their lawful roles require, while protecting unrelated confidential information. Provider will notify Sponsor promptly of a regulatory inspection or request relating to the Study and cooperate on responses, unless notice is prohibited.

7. Fees and changes

Sponsor will pay the fees and pass-through costs in Schedule 3 after accurate invoices and the corresponding milestones or units. Payment is due within [number] days. Sponsor must identify a good-faith dispute within [number] days and timely pay the undisputed remainder. Pass-through costs require the stated documentation and any required preapproval.

If assumptions materially change, Provider will notify Sponsor before performing affected extra work. No extra fee is due without a signed change order except documented action reasonably necessary to protect subjects or comply with an immediate legal requirement.

8. Confidentiality and inventions

Each party will use the other's nonpublic protocol, product, safety, technical, commercial, and personal information only for the Study, protect it with reasonable care, and disclose it only to authorized personnel. This excludes information independently developed, lawfully received without restriction, or public without breach. Legally required disclosure is permitted after prompt notice when lawful.

Inventorship is determined under applicable law. Each party owns inventions made solely by its personnel; jointly made inventions are jointly owned unless Schedule 3 states a lawful different allocation. Provider assigns to Sponsor the paid deliverables identified as Sponsor-owned and will obtain necessary personnel assignments. Publication by an investigator or institution is governed by its separate agreement and applicable ethical duties.

9. Insurance and responsibility

Each party will maintain the insurance stated in Schedule 3. Sponsor is responsible for investigational product or device risk, protocol design, and subject-injury arrangements allocated to it. Provider is responsible for its breach, negligence, willful misconduct, and failure to follow assigned lawful instructions. Neither allocation limits a subject's rights or a liability that law does not permit the parties to limit.

10. Termination and closeout

Either party may terminate for material breach not cured within [number] days after detailed notice, or immediately for a serious subject-safety threat, regulatory prohibition, fraud, or insolvency. Sponsor may terminate the Study for scientific, safety, regulatory, or business reasons on [number] days' notice.

Provider will promptly stop affected activity safely, protect subjects, preserve blinding and records, account for investigational materials, complete required safety reporting, transfer paid deliverables and records, revoke system access, and perform the closeout in Schedule 1. Sponsor will pay conforming Services and noncancelable approved costs through termination. Safety, privacy, records, confidentiality, ownership, inspection, payment, and accrued remedies survive.

11. General

Provider is an independent contractor and may not bind Sponsor. Neither party may assign this agreement without written consent except to a lawful successor that assumes it and can perform the regulatory duties. This agreement, protocol, schedules, and signed change orders are the entire agreement; Schedule 1 states the order of precedence. Pennsylvania law governs, without displacing mandatory federal or other site law. Electronic signatures and counterparts are permitted.

SCHEDULE 1 - STUDY AND SERVICES

Protocol/version, product/device, phase, countries and sites, Services, deliverables, timelines, systems, data and roles, subcontractors, closeout, assumptions, and order of precedence: [details].

SCHEDULE 2 - RESPONSIBILITY AND SAFETY MATRIX

For each sponsor, Provider, investigator, site, IRB, and regulator task: owner, authority, records, notice recipient, reporting deadline, consent/approval prerequisite, monitoring, and retention period: [details].

SCHEDULE 3 - BUDGET, INSURANCE, AND INTELLECTUAL PROPERTY

Fees, units, milestones, pass-through costs, invoice support, insurance, subject-injury allocation, deliverable ownership, invention allocation, and notice contacts: [details].

Sponsor: ____________________  Name and title: [name and title]  Date: [date]

Provider: ____________________  Name and title: [name and title]  Date: [date]


---
License: Licensed under CC BY 4.0. Attribution is required when you publish or redistribute this Template or an adapted version to the public. Attribution is not required merely because you use or adapt the Template for your own business or legal purposes, including preparing, negotiating, signing, or exchanging an agreement with a counterparty. License details.
License details: https://contract-templates.getfebruary.ai/license/